18 August 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce positive results from a second interim analysis of its RAPPER II clinical trial. RAPPER II is multi-centre, international trial to evaluate the feasibility and safety of the […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-08-18 21:49:512018-01-05 19:41:16Rex Bionics – More Positive Data from RAPPER II
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-08-16 21:50:322018-01-04 21:51:04Adherium and AstraZeneca Australia Commercial Pilot Program
05 August 2016: Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is today pleased to announce that Maxhealth Medicine Co. Ltd has now deposited £1 million in escrow in relation to its subscription for 3,333,333 ordinary shares at 30p each. This £1 million will […]
Melbourne, Australia, 4 August 2016: Link here. Adherium has appointed its new Chief Operating Officer, Ross Bradding, and a new Head of Corporate Development, Julia Chambers.
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-08-04 21:52:212018-01-04 21:52:46Adherium Build Senior Leadership Team with New Chief Operating Officer and New Head of Corporate Development
Wednesday, August 3, 2016 8:45 am EDT SAN DIEGO–(BUSINESS WIRE)–Link here. AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has completed enrollment of its Phase 1 clinical trial to evaluate the safety of AB-SA01, its proprietary phage cocktail targeting Staphylococcus aureus (S. […]
DUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation by Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-07-20 21:54:272018-01-05 19:44:05Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference
NZX / MEDIA RELEASE 18 July 2016. Link here. SeaDragon appoints new Chief Executive Dr Nevin Amos to take the reins of the company in October 2016. SeaDragon Board thanks outgoing Interim Chief Executive Richard Alderton for leadership through the company’s transition to Omega-3 fish oil markets SeaDragon, New Zealand’s largest refiner and blender of […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-07-14 21:53:522018-01-05 19:42:06Saluda Medical featured in Nature Journal
Northridge, CA, Perth, Australia and London, United Kingdom – 11 July 2016 Avita Medical Ltd today announced a partially underwritten non-renounceable rights issue to raise up to approximately $11m (Rights Issue) to support the Company’s strategy to launch in the US and push forward with product commercialization. Link here.
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-07-11 21:56:162018-01-04 21:56:48Avita Medical announces Rights Issue raises $9 million
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-06-29 21:56:572018-01-04 21:57:28Avita Medical scoops One Nucleus Summer BioNewsRound Award 2016
Rex Bionics – More Positive Data from RAPPER II
/in Portfolio Companies, Rex Bionics18 August 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce positive results from a second interim analysis of its RAPPER II clinical trial. RAPPER II is multi-centre, international trial to evaluate the feasibility and safety of the […]
Adherium and AstraZeneca Australia Commercial Pilot Program
/in Portfolio CompaniesMelbourne, Australia, 16th August 2016 Link here.
Rex Bionics – Confirmation of Strategic Investment by Maxhealth
/in Portfolio Companies, Rex Bionics05 August 2016: Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is today pleased to announce that Maxhealth Medicine Co. Ltd has now deposited £1 million in escrow in relation to its subscription for 3,333,333 ordinary shares at 30p each. This £1 million will […]
Adherium Build Senior Leadership Team with New Chief Operating Officer and New Head of Corporate Development
/in Portfolio CompaniesMelbourne, Australia, 4 August 2016: Link here. Adherium has appointed its new Chief Operating Officer, Ross Bradding, and a new Head of Corporate Development, Julia Chambers.
AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
/in Portfolio CompaniesWednesday, August 3, 2016 8:45 am EDT SAN DIEGO–(BUSINESS WIRE)–Link here. AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has completed enrollment of its Phase 1 clinical trial to evaluate the safety of AB-SA01, its proprietary phage cocktail targeting Staphylococcus aureus (S. […]
Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation by Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short […]
SeaDragon appoints new Chief Executive
/in Portfolio Companies, SeaDragonNZX / MEDIA RELEASE 18 July 2016. Link here. SeaDragon appoints new Chief Executive Dr Nevin Amos to take the reins of the company in October 2016. SeaDragon Board thanks outgoing Interim Chief Executive Richard Alderton for leadership through the company’s transition to Omega-3 fish oil markets SeaDragon, New Zealand’s largest refiner and blender of […]
Saluda Medical featured in Nature Journal
/in Portfolio Companies, Saluda MedicalBiomedicine: Move over, morphine James Mitchell Crow Nature 535, S4–S6 (14 July 2016) Published online 13 July 2016 Link here.
Avita Medical announces Rights Issue raises $9 million
/in Portfolio CompaniesNorthridge, CA, Perth, Australia and London, United Kingdom – 11 July 2016 Avita Medical Ltd today announced a partially underwritten non-renounceable rights issue to raise up to approximately $11m (Rights Issue) to support the Company’s strategy to launch in the US and push forward with product commercialization. Link here.
Avita Medical scoops One Nucleus Summer BioNewsRound Award 2016
/in Portfolio CompaniesNorthridge, CA, Perth, Australia and London, United Kingdom – 29 June 2016 Link here.